The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening
Cet article analyse l'utilité clinique de l'ADN tumoral circulant dans le dépistage, le diagnostic et le dépistage des cancers
In recent years, blood tests that look for circulating tumor DNA and biomarkers (termed liquid biopsies) have been developed. As Carr and Welch describe in this issue of JAMA Internal Medicine, these tests are being explored for diagnosis of suspected cancer, cancer surveillance after treatment, response to therapy, and chemotherapeutic selection. Most importantly, these blood tests are also being explored as multicancer early detection (MCED) tests for cancer screening in asymptomatic persons. Before US Food and Drug Administration (FDA) approval, insurer coverage, and clinical adoption of these technologies, rigorously conducted randomized clinical trials (RCTs) must be conducted demonstrating reductions in all-cause mortality to ensure that potential harms associated with these novel technologies do not exceed potential benefits.
JAMA Internal Medicine , éditorial, 2022